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http:WHAT THIS PAPER ADDS
This study is one of the ﬁrst to compare blood constituents in varicose veins with systemic blood. In varicose
veins there are increased levels of inﬂammatory markers, indicators of endothelial damage, and increased
procoagulant activity. These ﬁndings support the assumption that the constitution of blood in varicose veins
differs from that of systemic blood. This is the consequence of changes of blood ﬂow and deterioration of
hemodynamic forces, which could be involved in progression and complications of varicose veins.Objective: Varicose veins represent one of the most frequent vascular diseases and are in most cases benign.
However, advanced disease is frequently associated with complications such as chronic venous insufﬁciency and
superﬁcial vein thrombosis. The pathogenic mechanisms are not well understood. Besides increased venous
pressure, it is suggested that local blood constituents trigger various mechanisms responsible for the progression
of the disease and its complications.
Design: The aim of this study was to investigate the changes in the blood in varicose veins and to compare them
with the systemic markers of inﬂammation and endothelial damage.
Materials and methods: Forty patients with primary varicose veins were included in the study. Most patients
were class C2. Blood samples were taken from the leg from the tortuous and dilated varicose tributaries of the
great saphenous vein and from the cubital vein.
Results: The values of basic hematologic tests were comparable between blood samples (varicose vs. systemic).
In varicose veins, the following parameters were signiﬁcantly increased in comparison with systemic blood: hsCRP
(3.12  2.18 mg/L vs. 2.04  2.21 mg/L, p ¼ .04), IL-6 (3.54  2.59 pg/mL vs. 2.25  1.27 pg/mL, p ¼ .008), vWF
(118.4  27% vs. 83.2  22%, p < .05). D-dimer, in samples taken from the leg varicose veins, was also
signiﬁcantly higher than in the systemic blood (104.3  9.3 ng/mL vs. 89.5  8.3 ng/mL, p ¼ .039).
Conclusions: Some inﬂammatory markers and indicators of endothelial dysfunction are increased in varicose vein
blood. This is most probably the consequence of deteriorated blood ﬂow in dilated and tortuous superﬁcial veins,
and increased venous pressure. Damage to the venous wall, which causes a chronic inﬂammatory response,
together with the procoagulant properties of local blood may promote further progression of the disease and
thrombotic complications.
 2015 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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Varicose veins are dilated, tortuous, and elongated veins
especially affecting the superﬁcial veins of the lower limbs.
The disease is one of the most frequent manifestations of
vascular pathology.1 In developed countries, the prevalenceresponding author. Department of Vascular Disease, University
l Centre Ljubljana, Zaloska 7, SI-1000 Ljubljana, Slovenia.
il address: pavel.poredos@kclj.si (P. Poredos).
-5884/ 2015 European Society for Vascular Surgery. Published by
r Ltd. All rights reserved.
//dx.doi.org/10.1016/j.ejvs.2015.04.031of chronic venous disease is about 40e60% in females and
15e30% in males,2 and the annual incidence is 2.6% in
women and 1.9% in men.3 The prevalence of varicose veins
varies from 2% to 56% in men and 1% to 60% in women.4
According to the etiology, primary and secondary forms
should be distinguished, with the latter usually occurring as
consequence of deep vein thrombosis. The exact cause of
the primary varicosities is not yet completely understood,
but various theories of primary varicose vein pathophysi-
ology exist. As early as in the seventeenth century, Sir
William Harvey postulated that varicose veins develop as a
consequence of central valvular incompetence related to
valve atrophy. This could cause venous hypertension, which
Table 1. Clinical characteristics and the presence of risk factors in
40 subjects with varicose veins.
Parameter
Age, years 54.2  11.3
Sex, male 4 (10%)
Arterial hypertension 16 (40%)
Mean systolic BP, mmHg 131.5  12.7
Mean diastolic BP, mmHg 83.4  7.6
BMI, kg/m2 29.7  4.6
Diabetes mellitus 4 (10%)
Positive family history 34 (85%)
Hyperlipidemia 8 (20%)
Smoking 15 (37.5%)
Data are expressed as mean  standard deviation (SD) for
continuous variables and as numbers (N) and percentages (%)
for categorical variables.
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propagation of the disease.5 This theory from the seven-
teenth century was later substituted with primary vein wall
weakness theories, which state that varicose veins develop
from an inherited defect in vein wall integrity. Varicose
veins exhibit proliferation of collagen matrix with disruption
and distortion of muscle ﬁbers. Primary vein wall weakness
can also lead to valvular incompetence and venous hyper-
tension.6 The data also indicate that deterioration of venous
endothelial function could be involved in the pathogenesis
of varicose veins, which is predominantly a consequence of
decreased bioavailability of nitric oxide (NO).7 Nitric oxide is
an important cellular signaling molecule and a potent
vasodilator, which inhibits platelet adherence and aggre-
gation and reduces the adherence of leukocytes to the
endothelium. It has also been shown to inhibit proliferation
of vascular smooth muscle cells. Thus the deterioration of
vessel wall homeostasis caused by decreased bioavailability
of NO results in changes in vascular tone and platelet
adhesion, and ﬁnally morphologic deterioration of the
vascular wall.
Progression of deterioration of the venous wall and
valves leads to various clinically signiﬁcant complications,
such as chronic venous insufﬁciency including venous ul-
cers, thrombophlebitis, and an impact on the deep venous
system. In addition to turbulent blood ﬂow in tortuous
veins and venous hypertension, local blood changes in
varicose veins including increased thrombotic potential and
inﬂammation are most likely involved in the development
of complications. Therefore, impaired venous drainage of
the lower extremities determines a cascade of pathologic
events leading to chronic venous insufﬁciency. One of the
theories suggests that the venous hypertension causes red
blood cell extravasation and local iron overload that could
generate free radicals and iron dependent inﬂammation.
One of the studies showed that iron deposits in varicose
veins and tissue oxidative state measured by proton
induced X-ray emission spectroscopy correlate with iron
deposition, and this is related to oxidative stress, which
could inﬂuence the progression of chronic venous disease.8
However, the role of local changes in blood constituents in
disease progression and development of complications in
varicose veins has not been fully elucidated. Therefore, the
aim of this study was to compare the levels of markers of
inﬂammation and of coagulation/ﬁbrinolysis in varicose
veins with systemic levels (the blood taken from cubital
veins).PATIENTS AND METHODS
The study population consisted of 40 patients with primary
varicose veins that were scheduled for outpatient
sclerotherapy.
The clinical characteristics of the patients included in the
study are presented in Table 1. Although patients of both
sexes were recruited, there were only four males. Most
patients had increased body mass index, and in most there
was a family history of varicose veins. BMI > 30 kg/m2deﬁned obesity. Dyslipidemia was deﬁned as total choles-
terol > 4.5 mmol/L, LDL cholesterol > 4.5 mmol, LDL
cholesterol> 3.0 mmol/L, and /or triglycerides> 2 mmol/L.
The diagnosis of primary varicose veins was performed by
clinical examination and bilateral venous duplex ultrasound
scanning. Both the superﬁcial and deep venous systems
were examined.
Ultrasound examination of the deep veins was performed
in patients lying in the supine position with head elevation
of 15 to 30. All examinations followed a standard proto-
col, both legs were scanned. Transverse and longitudinal
imaging was done with a 10 MHz linear array probe (Vivid 7,
GE Medical Systems). The leg was ﬂexed at the knee and the
hip was externally rotated to allow the best exposure of the
junction of the common, deep, and superﬁcial femoral veins
as well as the popliteal fossa. The probe was held both
transverse and perpendicular to the skin surface. The ex-
amination was started as proximally as possible, ideally at
the inguinal ligament. The common femoral vein and artery
were identiﬁed ﬁrst, then the great saphenous vein
emptying into the common femoral vein was scanned and
the examination proceeded distally to the junction of the
common femoral, superﬁcial femoral, and deep femoral
veins. Finally, the probe was placed in the popliteal fossa for
visualization of the popliteal vein and artery and the prox-
imal calf veins. Compressibility was assessed in the trans-
verse plane, while the presence of venous ﬂow and valvular
reﬂux were measured in the longitudinal plane.
Investigation of the superﬁcial venous system was per-
formed in the standing position, because in this position
veins become fully distended and the identiﬁcation of reﬂux
was most reliable. Different transducer positions were used
with both longitudinal and transverse views. Examination
started in the groin, where compressibility and reﬂux of
sapheno-femoral junction and its tributaries and their reﬂux
were registered. The diameter of the great saphenous vein
in the thigh was measured, if reﬂux was present. Further,
the course of the great and small saphenous veins from the
knee to the ankle was examined by B mode scan of
branches and perforating veins. Examination of the poste-
rior tibial perforating vein and sapheno-popliteal junction
compressibility, ﬂow, and reﬂux were recorded.
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performed to exclude occlusion and to identify the location
and sources of tributaries of the GSV, and to identify reﬂux
and its source.
All patients were characterized as having primary vari-
cosities, while those with secondary varicosities were
excluded. The clinical, etiological, anatomical, and patho-
logical elements classiﬁcation system (CEAP) was used to
classify chronic lower extremity venous disease (CVD).9
Most were class C2 (31 patients, 78%), and the others (9
patients, 22%) were class C3. The exclusion criteria for the
study were a history of deep vein thrombosis, post-
thrombotic syndrome, reﬂux in the deep venous system,
active skin ulcers or local skin inﬂammatory changes,
Klippel-Trenaunay syndrome, May-Turner syndrome, recent
infection, neoplastic disease, and chronic systemic inﬂam-
matory disease.
Blood samples were taken from the upper and lower
extremity with the patient in a supine position. The supine
position was chosen to eliminate the inﬂuence of hydro-
static pressure on the release of circulating markers. Blood
samples from the leg were obtained above knee from the
tortuous and dilated varicose tributaries of the great
saphenous vein (local) and from the antecubital vein by
standard venepuncture (systemic). The plasma, obtained by
centrifugation of citrated venous blood at 5000 rpm for 5
minutes, was immediately frozen at 70 C for subsequent
testing. Measurements were preformed within 3 months.Laboratory methods
The erythrocytes, leukocytes, platelets, hemoglobin, and
hematocrit were determined using a Cobas Minos STX de-
vice for automatic hematology measurements (Roche,
Basel, Switzerland).
Serum concentrations of inﬂammatory, procoagulant,
and endothelial markers were determined using commer-
cially available kits according to the manufacturers’ in-
structions. Fibrinogen concentration was determined
according to the Clauss method,10 which is based on
determination of ﬁbrinogen with thrombin clotting time,
using commercially available reagents (Multiﬁber, Behring,
Marburg/Lahn, German). D-dimer was determined by an
immunoturbidimetric assay Auto-Dimer (Axis-Shield, Swe-
den) on an automated coagulation analyzer CS2100i (Sys-
mex, Japan). High sensitivity C-reactive protein (hsCRP) was
determined by an immunoturbidimetric assay (Vitros Fusion
5.1, Ortho-Clinical Diagnostics, USA). The concentrations of
human tumor necrosis factor-a (Quantikine HS High Sensi-
tivity, Human TNF-a Immunoassay, R&D Systems, Minne-
apolis, USA), interleukin-6 (Quantikine HS High Sensitivity,
Human IL-6 Immunoassay, R&D Systems, USA), activity of
plasminogen activator inhibitor-1 (PAI-1) (TriniLIZE PAI-1
Activity, Axis-Shield, Sweden), von Willebrand factor (vWF)
antigen (Axis-Shield, UK), plasminogen activator inhibitor-1
(PAI-1) antigen (TriniLIZE PAI-1 Antigen, Axis-Shield, Swe-
den), and tumor necrosis factor receptor 1 TNF R-1
(Quantikine HS High Sensitivity, TNF R 1 Immunoassay, R&DSystems, USA), were measured by enzyme linked immuno-
sorbent assay (ELISA) using commercially available kits ac-
cording to the manufacturers’ instructions.
Determination of neuron speciﬁc enolase (NSE) was per-
formed using the LIASON NSE method, which is a fully auto-
mated monoclonal double (sandwich) chemiluminescence
immunoassay, where the serum is incubatedwith an antibody
coated magnetic particle and a luminescence labeled tracer.
The resulting luminescence is indicative of the amount of NSE
in the sample.
Neutrophil gelatinase associated lipocalin (NGAL) was
measured by particle enhanced turbidimetric assay using a
Cobas c501 automated biochemistry analyzer (Roche, Man-
nheim, Germany).Statistical analysis
Parametric values were expressed as mean and standard
deviation. The differences between groups were compared
by independent samples t test. Pearson correlation analyses
were used in the statistical evaluation of the relationship
between various parameters. All statistical tests were two
sided, and p values of 0.05 or less were considered signif-
icant. All data analyses were performed using SPSS for
Windows version 21.0 (SPSS, Inc., Chicago IL, 2012).
Informed written consent was obtained from all patients
fulﬁlling the entry criteria. The study protocol was approved
by the regulations of the state ethical committee and
conducted in accordance with the Declaration of Helsinki.
RESULTS
The main clinical characteristics and anthropometric data
are presented in Table 1. Forty patients with varicose veins,
mostly females, were included in the study. According to
the CEAP classiﬁcation the patients were class C2 (31, 78%)
and C3 (9, 22%). With the exception of positive family his-
tory which was present in most of the patients (84%), the
presence of other atherosclerosis risk factors was rare. Most
women had increased body weight and body mass index.
Medication, mostly for atherosclerosis risk factors included
ACE inhibitors (40%) and statins (22.5%). Four patients with
diabetes mellitus were all treated with hypoglycemic drugs.
The inﬂammatory markers, ﬁbrinolytic markers, and
markers of endothelial damage of systemic and local blood
are presented in Table 2. Most of the hematological pa-
rameters were within the normal range and there were no
signiﬁcant differences between varicose and cubital veins.
However, some circulating inﬂammatory markers (hs CRP)
and interleukin 6 (IL-6), as well as D-dimer and vWF
(Table 2) were signiﬁcantly increased in the blood samples
taken from varicose veins. There was a strong positive
correlation for the CRP levels (r ¼ 0.98, p < .01) and a
signiﬁcant correlation for D-dimer levels (r ¼ 0.698,
p < .038) between varicose and cubital vein samples.
Despite comparable values of soluble tumor necrosis factor
1 (TNF-1) in both samples, there was a positive correlation
between varicose and cubital vein samples (r ¼ 0.681,
p < .01). The levels of microparticles were also similar
Table 2. Serum levels of inﬂammatory and ﬁbrinolytic markers
from the blood samples taken from varicose veins (local) and
cubital veins (systemic).
Parameter Systemic blood Local blood p
Erythrocytes, 1012/L 4.56  0.35 4.51  0.36 .47
Hemoglobin, g/L 135.38  10.28 134.04  10.68 .53
Hematocrit, L 0.42  0.03 0.41  0.03 .439
Leukocytes, 109/L 6.96  1.64 7.51  1.59 .096
Thrombocytes, 109/L 242.50  61.62 236.73  63.84 .652
hs CRP, mg/L 2.04  2.21 3.18  1.87 .04a
Fibrinogen, g/L 3.46  0.95 3.48  0.95 .93
D-dimer, ng/mL 89.5  8.3 104.3  9.2 .039a
PAI-1 activity, IE/mL 2.99  3.36 3.32  3.56 .647
PAI-1 antigen, pg/mL 13.43  8.22 16.25  10.28 .157
vWF, % 83.2  22 118.4  27 .005a
IL-6, pg/mL 2.25  1.27 3.54  2.59 .008a
TNF alpha, pg/mL 1.33  0.57 1.37  0.64 .785
NSE, ng/mL 3.83  4.55 2.37  1.27 .066
NGAL, ng/mL 299.18  107.34 316.93  88.68 .447
TNFR 1, ng/mL 0.50  0.15 0.53  0.13 .451
MP, Nr/mL 2.56  2.31 3.76  7.58 .362
Data are expressed as mean  SD.
hs CRP ¼ high sensitive C-reactive protein; PAI-1 ¼ plasminogen
activator inhibitor-1; vWF ¼ von Willebrand factor; IL-
6 ¼ interleukin 6; TNF alpha ¼ tumor necrosis factor alpha;
NSE ¼ neuron speciﬁc enolase; NGAL ¼ neutrophil gelatinase
associated lipocalin; TNFR1 ¼ tumor necrosis factor receptor 1;
MP ¼ microparticles.
a Statistically signiﬁcant.
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observed between the varicose and cubital samples. The
levels of inﬂammatory markers and ﬁbrinolytic indicators
were not correlated with the location or the duration of the
disease.
Separate subgroup analysis of patients in class C2 and C3
with the exception of a higher BMI in the C3 group of pa-
tients (class C2 27.8  4.0 kg/m2, class C3 31.7  5.1 kg/m2,
p < .05) did not show any other signiﬁcant anthropometric
difference between the groups. Also the values of circula-
tory markers were comparable between the groups.DISCUSSION
Various factors are believed to play a role in the patho-
genesis of primary varicose veins and their complications.
Endothelial dysfunction increases the inﬂammatory
response and oxidative stress is often implicated in the
pathogenesis of these disorders.
The primary pathogenic mechanism of varicose veins is
probably dilation of veins with incompetent valves and
consequential development of venous stasis and venous
hypertension. Hemodynamic deterioration in varicose veins
increases oxidative stress, inﬂammation, and procoagulant
and antiﬁbrinolytic activity. All these factors promote pro-
gression of the disease and development of complications
including chronic venous insufﬁciency.
The present study focused on investigating blood con-
stituents: inﬂammatory markers, indicators of endothelial
damage, and ﬁbrinolysis in varicose veins, and on testing forany signiﬁcant difference between varicose and cubital vein
blood. It was hypothesized that changes in the local he-
modynamics because of turbulent ﬂow in dilated and
tortuous veins causes an increased release of different in-
ﬂammatory and endothelial markers. To homogenize the
group, only patients in class C2 and class C3 without any
local skin inﬂammatory changes were included.
To the authors’ knowledge, this is the ﬁrst study to
compare the levels of markers of inﬂammation, endothelial
damage, and ﬁbrinolysis in local blood (varicose vein) with
levels in systemic blood in the same subjects. In 1929,
Blalock reported that the carbon dioxide content of the
varicose blood is higher than that of the venous blood in
the cubital vein of the same person, and that the oxygen
content was lower in varicose veins.11 A study by Asciutto
and co-workers showed that in varicose veins, rising from
the great saphenous vein, estradiol levels were signiﬁcantly
higher than in veins of the upper extremity.12
In the present study, some inﬂammatory markers were
increased in the varicose vein samples compared with the
systemic blood. In varicose vein blood, signiﬁcantly
increased levels of hs CRP and IL-6 were found. A borderline
(insigniﬁcant) increase of leukocytes in the varicose vein
blood was also recorded.Varicose veins and inﬂammation
Evidence has accumulated to support the role of venous
hypertension and shear stress in the development of
inﬂammation both of the wall of the veins and in the sur-
rounding tissue.13 It is generally agreed that laminar shear
stress promotes the release of factors that suppress
inﬂammation and reactive free radical production, while
low shear stress, turbulent ﬂow, and stasis promote the
production of inﬂammation and thrombotic mediators.14
Therefore, venous stasis promotes the inﬂammation and
deterioration of the venous wall. Studies have shown that
plasma markers of leukocyte activation and vascular cell
adhesion molecules are increased after subjecting patients
with varicose veins to 30 minutes standing to induce venous
hypertension.15 Therefore, an increased local inﬂammatory
response and hypercoagulability in the convolutions of the
varicose veins was expected in this study. This is probably a
consequence of damage to the vessel wall because of tur-
bulent venous ﬂow and chronically increased venous pres-
sure. The data indicate that inﬂammation and hemostasis
are coupled with common activation pathways and a
feedback regulation system. During inﬂammation, the hae-
mostatic balance may be disturbed, resulting in increased
production of procoagulant factors and the downregulation
of anticoagulant mechanisms.16 Inﬂammation also inhibits
ﬁbrinolytic activity, as conﬁrmed by the negative relation-
ship between some inﬂammatory markers and tPA activity.
However, the crosslink between inﬂammation and hemo-
stasis is complex and involves different reactions, endo-
thelial damage, and the production of cell derived
microparticles.17 Therefore, local inﬂammation of the
deteriorated varicose vein wall may be involved in
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is known that thrombosis of superﬁcial veins appears in
90% of cases of varicose veins.18
Few studies have investigated systemic inﬂammation in
patients with varicose veins, and reports on inﬂammatory
markers in varicose veins are very rare. One study found a
marked expression of monocyte chemoattractant protein-1,
macrophage inﬂammatory protein, interferon inducible
protein-10, and interleukin-8 in varicose veins. The authors
suggested that these chemokines might play an important
role in the pathophysiology of varicose veins and compli-
cations by recruiting leukocytes to the vein wall and
contributing to inﬂammation.19
One of the most interesting ﬁndings of the present study
is the signiﬁcantly increased level of IL-6 in varicose veins.
IL-6 acts as an inﬂammatory cytokine. It is secreted by the T-
cells and macrophages to stimulate the immune response
to trauma or other tissue damage leading to inﬂammation.
It is also involved in the regulation of metabolic, regener-
ative, and neural processes.20 This ﬁnding supports the idea
of the increased inﬂammatory response as a consequence
of chronic damage of the vessel wall caused by turbulent
blood ﬂow, promoting the coagulation process. There are no
data in the literature on the levels of IL-6 in varicose veins in
comparison with the blood taken from the brachial vein.
The only report on the systemic levels of IL-6, from Yasim
and co-workers, did not show signiﬁcant differences in
systemic levels of IL-6 between patients with varicose veins
and healthy subjects.21
In the present study, a borderline increase of neuron
speciﬁc enolase (NSE) was found. This glycolytic enzyme is
produced by neuronal and neuroendocrine cells and is used
as a tumor marker of neuroendocrine cancers.22 There are
no data on the involvement of NSE in the pathogenesis of
varicose veins or on its role in the development of com-
plications related to varicosities. NSE is probably an indi-
cator of vascular damage related to the local inﬂammatory
response of the venous wall, and may stimulate procoa-
gulant activity of blood.23Endothelial dysfunction and varicose veins
According to Virchow’s triad, endothelial dysfunction and
injury of the venous wall represent one of the basic
mechanisms not only for the development of deep vein
thrombosis, but also most probably for the development of
varicose veins and complications (thrombosis). Trauma to
the endothelium and damage arising from shear stress of
venous hypertension (endothelial dysfunction) are expected
in varicose veins. Endothelial dysfunction is probably the
starting point of venous wall cell damage in patients with
varicose veins.
In this study, von Willebrand factor levels were measured
to evaluate endothelial activity and/or damage, as this
factor is generated by endothelial cells. It is continuously
synthesized and released into the blood in physiological
conditions, as it participates in coagulation and in theformation of platelet plugs at the sites of endothelial
damage. Its levels are increased in subjects with athero-
sclerotic risk factors and situations characterized by vascular
damage. In this study, vWF was signiﬁcantly increased in
varicose vein compared with systemic blood.
The vascular endothelium is an important regulatory or-
gan in maintaining cardiovascular homeostasis. Normal
endothelial function includes control over thrombosis and
thrombolysis, platelet and leukocyte interaction with the
vessel wall, regulation of vascular tone, and smooth muscle
cell proliferation. One of the most important regulatory and
vasoactive substances produced by the endothelial cells is
nitric oxide (NO). Nitric oxide modulates vascular tone and
inhibits the interaction between blood cells and the vessel
wall. Endothelial damage caused by mechanical, metabolic,
or chemical factors contributes to disease characterized by
inﬂammation, vasoconstriction, excessive thrombus forma-
tion, and the adhesion of leukocytes to the vessel wall.24
Therefore, endothelial dysfunction is not only involved in
the pathogenesis of atherosclerosis but also plays a role in
the progression of varicose veins and thrombotic compli-
cations - superﬁcial venous thrombosis. Endothelial
dysfunction can, through changes of vasomotion, directly
inﬂuence the venous ﬂow, and can cause an imbalance
between the pro- and anticoagulant activity of endothelial
cells with the release of procoagulant factors and the
reduced release of proﬁbrinolytic substances, as was also
conﬁrmed in the present study. Therefore, it can be
concluded that in varicose veins there is an imbalance be-
tween pro- and anticoagulant as well as between pro- and
antiﬁbrinolytic factors, with a prevailing prothrombotic
state.
Until now, no study has compared the levels of procoa-
gulant and ﬁbrinolytic markers as well as markers of
endothelial damage in varicose veins with the systemic
levels of these markers in the same subjects. One study
compared the systemic concentrations of procoagulant and
endothelial markers in patients with primary varicose veins
with those in healthy subjects and found no statistically
signiﬁcant differences in the plasma (systemic) levels of
protein C, ﬁbrinogen, tPA, IL-6, and NO between the study
and control groups.21 However, in that study, in contrast
with the present study, circulating markers between
different groups in systemic blood were compared and this
ﬁnding does not exclude an increased local release of in-
ﬂammatory markers and markers of endothelial damage.
When they are diluted in systemic blood, signiﬁcant dif-
ferences can be masked and disappear. Therefore, it seems
likely that increased levels in local blood are more indicative
of damage and inﬂammation of the local vascular segment
and deterioration of the vessel wall, than levels in the
systemic blood.
In the present study, D-dimer was elevated in varicose
vein samples and a positive was evident correlation be-
tween the varicose and cubital vein samples. These ﬁndings
suggest increased local formation of ﬁbrin, which is prob-
ably the consequence of damage to the vessel wall and
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potential, which can induce thrombus formation and su-
perﬁcial venous thrombosis.
Limitations of this study
To answer the question of whether subjects with varicose
veins have not only increased local but also systemic
markers of inﬂammation and endothelial damage, healthy
subjects (controls) would be needed to allow for compari-
son of the systemic levels of the investigated markers. There
are some studies in which systemic levels of circulating
markers were compared; however, the aim of the present
study was to compare the levels of investigated markers in
varicose veins with those in cubital veins, and to determine
whether speciﬁc hemodynamic conditions in varicose veins
cause these markers to be intensively released locally in the
varicose veins compared with systemic blood.
For technical reasons, this study did not include an
investigation of oxidative stress, which is probably one of
the most important pathogenic factors for the development
of varicose veins and related complications.
As most patients in this study were CEAP stage C2, it
would be interesting to investigate the levels of different
markers in patients with advanced chronic venous disease
(C4-C5) and to investigate whether oxidative stress markers,
inﬂammatory markers, and markers of endothelial damage
increase with the progression of disease. However, in
advanced stages with leg ulcers and skin inﬂammation,
levels of circulatory markers could be inﬂuenced by
inﬂammation and not only by hemodynamic changes
caused by dilated varicose veins.
In conclusion, the results of this study indicate that in
comparison with the systemic blood, some inﬂammatory
markers and markers of endothelial damage are increased
in varicose vein blood. Chronic local inﬂammation of the
vein wall and endothelial dysfunction are most probably the
consequence of stasis of venous blood and increased
venous pressure. Furthermore, turbulent blood ﬂow in
tortuous and dilated veins is most probably another trigger
of inﬂammation and coagulation. All these hemodynamic
factors and changes of blood constituents promote disease
progression and are most probably responsible for compli-
cations including superﬁcial vein thrombosis and chronic
venous insufﬁciency.
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